BACKGROUND AND AIM
Pharmacovigilance is essential to ensuring patient safety by enabling timely identification of adverse reactions in increasingly complex and voluminous data. Routine quantitative signal detection methods generate statistical alerts for product-event pairs based on predefined criteria; however, most alerts do not warrant further investigation, creating inefficiencies and significant time demands for pharmacovigilance teams. Manual triage of these alerts is often resource-intensive, prone to variability, and challenging to audit, highlighting the need for more reliable, transparent and efficient triage strategies. This study aimed to design, develop and prospectively evaluate an explainable Machine Learning for Intelligent Triage (MLIT) tool to assist pharmacovigilance teams in reviewing statistical alerts for vaccine and drug portfolios. The objective was to enhance signal detection performance without increasing the risk of missing signals, improving operational efficiency and maintaining decision traceability and regulatory compliance.
METHODS
Alert and individual case safety report data were retrieved from the company's safety and signal management databases. Feature selection was guided by prior experience with a published case completeness tool, called Clinical Utility Score for Prioritisation (CUSP), and expert input. Of several ML methods explored, eXtreme Gradient Boosting (XGBoost) emerged as the optimal algorithm, with models trained and tested using a 75/25 split dataset. Iterative model refinement was conducted using Shapley Additive Explanations analyses to ensure explainability and alignment with safety reviewers' decision-making processes. Refined models underwent prospective validation in two four-month prospective validation studies, covering over 20 products across vaccine and drug portfolios. The prospective validations assessed concordance between model predictions and reviewers' decision under real-world conditions, as well as estimated time savings.
RESULTS
The vaccine model demonstrated robust predictive performance, achieving a weighted-average F1 score of 0.81 and an accuracy of 0.79. In the prospective validation phase, 92% of vaccine alerts were closed in alignment with the model's top-ranked prediction, while 98% were closed within the top 3 predictions. The MLIT tool also identified inconsistencies and human errors in manual triage, highlighting its potential role as a quality-control mechanism. Safety reviewers reported a 24% reduction in time spent on triage activities, and explainability analyses confirmed that the model's decision-making was conceptually aligned with safety reviewers' logic. Comparable results were observed for the drug portfolio.
CONCLUSION
This study highlights the potential of ML-based tools to improve pharmacovigilance by enhancing signal detection performance, reducing the likelihood of missed signals, while increasing operational efficiency, and strengthening reproducibility and transparency. While MLIT demonstrated high concordance with expert decisions and provided meaningful time savings, human oversight remains essential, especially for low-confidence predictions. Ongoing refinement and user engagement will be critical for broader implementation and further automation, marking a significant step forward in ensuring safer and more efficient drug safety surveillance.
Luciano Ciccarelli, Olivia Mahaux, Christie Roshan et al.· Drug Safety· 0 citations
Drug safety remains central to patient benefit, as maximizing the value of beneficial therapies requires recognition, appropriate characterization, and effective mitigation of treatment-related adverse drug reactions (ADRs). These challenges, particularly with the advent of artificial intelligence (AI) tools, have increased interest in predictive safety as a lifecycle scientific capability that seeks to anticipate plausible harm in a timely fashion and translate evolving evidence into more informed decisions across acquisitions, clinical development, and postmarketing use. In this article, predictive safety is used primarily to mean product-level and population- or subgroup-level anticipation of plausible treatment-related harm, rather than an autonomous patient-level clinical decision-making approach. Recent advances in AI, human genetics, mechanistic modeling, translational biomarkers, and real-world data have strengthened the scientific basis for this approach. However, predictive safety should never be viewed as a promise to eliminate ADRs or as a substitute for clinical judgment. Its value would be in improving prospective ADR characterization, supporting portfolio prioritization, and enabling timely and more targeted mitigation. In some settings, notably prospective genotype-based screening before exposure, it might prevent the reaction from occurring. This article argues for the development of a governed AI-supported predictive safety ecosystem. It outlines the reasons predictive safety is needed and the context in which it is most likely to add value. It also discusses principal implementation risks, including fragmented data, unstable phenotypes, model drift, transportability failure, and misuse of probabilistic outputs, together with practical mitigation strategies and leading indicators for early governance response.
Tarek A. Hammad, Justine Rochon, Kate Gofman et al.· Drug Safety· 0 citations
An overview of the CIOMS XIV guidance on Artificial Intelligence in Pharmacovigilance presents seven guiding principles and illustrates how these principles may be applied in practice through selected use cases.
G. N. Norén, Julie Durand, V. Kara et al.· Drug Safety· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.